Sanguedolce Francesca, Zanelli Magda, Zizzo Maurizio, Luminari Stefano, Martino Giovanni, Soriano Alessandra, Ricci Linda, Caprera Cecilia, Ascani Stefano
Pathology Unit, Policlinico Riuniti, University of Foggia, 71121 Foggia, Italy.
Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Cancers (Basel). 2021 Jun 3;13(11):2790. doi: 10.3390/cancers13112790.
iTLPD-GI is a low-grade clonal T-cell lymphoproliferative disease arising in GI organs. It is an uncommon disease, and only recently has it been enlisted as a distinct provisional entity in the current WHO Classification. Data from the literature disclose high heterogeneity in terms of pathological and molecular features; on the other hand, establishing an accurate diagnosis of iTLPD-GI is of pivotal importance, since treatment options are different from that of other, more frequent lymphomas that arise in the gastrointestinal tract. In this review, we aimed to better define this novel entity, and to identify useful diagnostic biomarkers; moreover, we provide a biomarker-based approach to the diagnosis and describe the most common issues in differentiating iTLPD-GI from other neoplastic and non-neoplastic disorders.
肠道原发性低度恶性克隆性T细胞淋巴增殖性疾病(iTLPD-GI)是一种发生于胃肠道器官的低度恶性克隆性T细胞淋巴增殖性疾病。它是一种罕见疾病,直到最近才被列入现行世界卫生组织分类中的一个独特的暂定实体。文献数据显示,其在病理和分子特征方面存在高度异质性;另一方面,准确诊断iTLPD-GI至关重要,因为其治疗方案与其他更常见的发生于胃肠道的淋巴瘤不同。在本综述中,我们旨在更好地定义这一新型实体,并识别有用的诊断生物标志物;此外,我们提供一种基于生物标志物的诊断方法,并描述在鉴别iTLPD-GI与其他肿瘤性和非肿瘤性疾病时最常见的问题。